Jazz to Present Seven Abstracts on Idiopathic Hypersomnia and Narcolepsy

Jazz Pharmaceuticals will present seven abstracts featuring new data from across its sleep medicine portfolio, encompassing idiopathic hypersomnia and narcolepsy, at SLEEP 2023 in Indianapolis. 

Presentations include four posters featuring real-world data on Xywav (calcium, magnesium, potassium, and sodium oxybates), the first and only low-sodium oxybate, for the treatment of narcolepsy patients with cataplexy and/or excessive daytime sleepiness (EDS) and adult patients with idiopathic hypersomnia.

“For almost two decades, we have strived to develop innovative therapies and provide meaningful support for people living with challenging neurological conditions. This is exemplified through our development of low-sodium Xywav,” says Kelvin Tan, senior vice president and chief medical officer of Jazz Pharmaceuticals, in a release. “As people living with narcolepsy or idiopathic hypersomnia have two-to-three times higher prevalence of cardiovascular comorbidities such as stroke and heart failure, and sodium is a modifiable risk factor for these cardiovascular conditions, having a low-sodium option is an important consideration for long-term health.”

Highlights at SLEEP 2023 include:

In idiopathic hypersomnia:

A real-world claims analysis of the clinical burden of patients diagnosed with idiopathic hypersomnia, which found they experienced significantly higher prevalence of comorbidities, such as cardiovascular conditions and mood disorders, than those not diagnosed with the sleep disorder. These results are consistent with previous studies in other sleep disorders, including narcolepsy, and confirm the need for holistic treatment strategies that consider patients’ overall clinical profile.

In narcolepsy:

Two posters on results of the real-world TENOR study of adults with narcolepsy transitioning from Xyrem, a high-sodium oxybate, to low-sodium Xywav, which demonstrated maintenance of effectiveness and tolerability upon switching to Xywav. One analysis investigated patient preferences and satisfaction of those who switched to Xywav, finding most patients preferred Xywav over Xyrem due to its lower sodium content. Another investigated patient-reported sleep quality among those who transitioned to Xywav and found a greater percentage of participants reported feeling refreshed at the end of the study on Xywav than at baseline on Xyrem.

The final analysis of the interventional SEGUE study that examined the safety, tolerability, effectiveness, and treatment optimization in adults with narcolepsy transitioning from high-sodium Xyrem to low-sodium Xywav. The analysis found the majority of patients reported the transition process was easy with minimal modifications of dose or regimen, maintaining effectiveness, and ultimately preferring low-sodium Xywav over Xyrem.

“Our data at SLEEP 2023 reaffirm our longstanding commitment to patient care and the sleep community. We look forward to sharing our research at the meeting and advancing the understanding of these multi-symptom and often underrecognized sleep disorders,” says Kelvin Tan, senior vice president and chief medical officer of Jazz Pharmaceuticals, in the release.

A full list of Jazz-sponsored presentations follows:

Source